title: [A case of advanced hepatoma cured by repeated percutaneous isolated liver perfusion using hepatic venous isolation and charcoal hemoperfusion].
abstract: We have reported the treatment results of percutaneous isolated liver perfusion using hepatic venous isolation and charcoal hemoperfusion (HVI.CHP) for unresectable liver cancers. This is a case of multiple advanced hepatoma cured completely by repeated per cutaneous isolated liver perfusion. The patient was a 58-year-old woman who was referred to our hospital for a hepatic tumor detected by abdominal computed tomograpy (CT). On admission, she showed HBs antigen positive, mild anemia and liver dysfunction, and elevation of tumor markers. Abdominal CT demonstrated nodular tumors in segment 4. In addition, hepatic angiography additionally revealed multiple bilobar metastases. We treated this case with high-dose intraarterial adriamycin (150 mg/body) using HVI.CHP. There after, the patient received intermittent intraarterial low-dose epirubicin infusions (30 mg/body, 5 times) via an implantable catheter system. Furthermore, she was given a second high-dose of adriamycin (130 mg/body) under HVI.CHP 7 months after the first treatment. Despite repeated high-dose treatments, she had no severe side effects. The levels of tumor markers, including AFP and PIVKA-II, decreased to normal range, and all tumor nodules have disappeared in abdominal CT studies at present, 20 months after the initial treatment. In conclusion, our experience suggests that advanced hepatoma with multiple bilobar lesions, as in this case, would be cured by repeated percutaneous isolated liver perfusion using HVI.CHP.
authors.affiliation: First Dept. of Surgery, Kobe University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Kitagawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ku
authors.forename: I
authors.initials: I
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Iwasaki
authors.forename: N
authors.initials: N
authors.lastname: Kusunoki
authors.forename: T
authors.initials: T
authors.lastname: Sugimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kuroda
authors.forename: Y
authors.initials: Y
authors.lastname: Saitoh
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D002606:Charcoal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006464:Hemoperfusion; D006503:Hepatic Veins; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008875:Middle Aged; D010477:Perfusion / Q000379:methods*
chemical_list: D002606:Charcoal; D015251:Epirubicin; D004317:Doxorubicin